<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03732508</url>
  </required_header>
  <id_info>
    <org_study_id>IRI-SHR-1316-201</org_study_id>
    <nct_id>NCT03732508</nct_id>
  </id_info>
  <brief_title>SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer</brief_title>
  <official_title>SHR-1316, a Novel Anti-PD-L1 Antibody, in Combination With Irinotecan Liposome and Fluorouracil in Patients With Esophageal Squamous Cell Cancer: a Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the progression-free survival (PFS) of Chemotherapy
      combined with SHR-1316 in patients with advanced esophageal squamous cell cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2018</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Progression-Free Survival (PFS)</measure>
    <time_frame>approximately 22 months</time_frame>
    <description>based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate(DCR)</measure>
    <time_frame>approximately 22 months</time_frame>
    <description>based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>approximately 22 months</time_frame>
    <description>based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>approximately 22 months</time_frame>
    <description>OS is defined as the time from registration to death due to any cause, or censored at date last known alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events(AE)</measure>
    <time_frame>approximately 22 months</time_frame>
    <description>adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Esophageal Squamous Cell Cancer</condition>
  <arm_group>
    <arm_group_label>Irinotecan liposome plus SHR1316 plus fluorouracil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan liposome</intervention_name>
    <description>Irinotecan liposome intravenous infusion will be administered during the first day of treatment.</description>
    <arm_group_label>Irinotecan liposome plus SHR1316 plus fluorouracil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1316</intervention_name>
    <description>SHR-1316 intravenous infusion will be administered during the first day of treatment.</description>
    <arm_group_label>Irinotecan liposome plus SHR1316 plus fluorouracil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Fluorouracil intravenous infusion will be administered during the first day of treatment.</description>
    <arm_group_label>Irinotecan liposome plus SHR1316 plus fluorouracil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed unresectable local advanced/recurrent or
             metastasis esophageal squamous cell carcinoma;

          2. No previous systemic anti-tumor treatment;

          3. Subjects must have at least one measurable tumor lesion per RECIST 1.1;

          4. ECOG: 0-1;

          5. Adequate organ and bone marrow function;

        Exclusion Criteria:

          1. Allergic to monoclonal antibodies, any SHR-1316 components,Irinotecan , Fluorouracil ;

          2. Prior therapy as follow:

               1. Anti-PD-1 or anti-PD-L1;

               2. Any experimental drugs within 4 weeks of the first dose of study medication;

               3. Received major operations or serious injuries within 4 weeks of the first dose of
                  study medication;

               4. Received last dose of anticancer therapy (including chemotherapy, radiotherapy,
                  targeted therapy, etc.) within 4 weeks of the first dose of study medication;

          3. Not recovered to â‰¤CTCAE 1 from adverse events (except for hair loss) due to a
             previously anti-tumor treatment;

          4. Subjects with any active autoimmune disease or history of autoimmune disease;

          5. Pregnancy or breast feeding;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Huang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fei Shi</last_name>
    <phone>+86-18036618733</phone>
    <email>hrshifei@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Institute and Hospital,Chinese Academy of Medical Science</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Huang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 31, 2018</study_first_submitted>
  <study_first_submitted_qc>November 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2018</study_first_posted>
  <last_update_submitted>November 5, 2018</last_update_submitted>
  <last_update_submitted_qc>November 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

